RE:RE:RE:RE:Competition waiting on FDA approval Eoganacht wrote: I'm fairly confident that Theralase will do far better than Viciniums's less than 17% CR rate at 12 months. Maybe even 4 times better.
enriquesuave wrote: SESN hit its yearly high of 6.04 today and yearly low of 0.70 following CRL from FDA. Maybe they know we have the goods and no one else compares. Just saying. All IMO. Feel sorry for SESN shareholders
This ACT certainly has the potential for "4 times" better efficacy.
May be a good time to throw in some of my thoughts/opinions for many of us smaller shareholders....The limitations of immunotherapy (IT) can be pronounced considering the multiple resistance mechanisms utilized by a variety of cancer cell types. A primary mechanism of resistance is not only related to the extensive cellular diversity across many cancer types, but also the cellular diversity/heterogeneity within a "single" type of cancer. Such cancer heterogeneity can significantly limit the benefits/efficacy of employing a single type of IT...a single cancer mutates & often evolves contemporaneously when exposed to various medical therapies. Both preexisting heterogeneity & therapeutic selection result in the presence of variant subsets of cells (sub clones) that can often evade IT...explains the recent uptick in research/studies using combined IT, which will result in better efficacy, but will likely be far from enough imo. The myriad mechanisms used by cancer to evade standard/current chemo, radiotherapy & IT will continue to exert a heavy toll...
This is where Theralase's ACT comes to the rescue. This ACT is demonstrating the ability to kill cancer irrespective of cancer/cancer cell type....& its ability to destroy multiple types of microorganisms further illustrates the true breadth & promise of this technology. The only obstacle remaining in my mind surrounds the physical/depth limitations in compound activation. I'm very much looking forward to the development of more targeted & simplified external forms of compound activation (x-ray, SBRT, proton beam therapy....really like the theoretical/clinical potential of the latter). Accomplishing more practical forms of activation would certainly expedite the marketability of this ACT...& if promising data keep rolling in, I really don't see how this technology remains in the lab & out of the mainstream, as either a solo or adjuvant therapy. IT could use a better partner....JMHO. GLTA!